Payment overview · 2025
General Payments
$764.34
49 reported records · 6 companies
Healthcare provider profile · identity verified
Stephen Grelecki, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · ELIZABETH, NJ · NPI 1508838665
Verified facts
What the public records show
CMS Open Payments records show Stephen Grelecki, MD received $764.34 in general payments during 2025 across 49 reported records.
ABBVIE INC. accounted for 46.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Caplyta, Invega Sustenna, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Aristada by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Invega Sustenna by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $357.22 | 46.7% | 25 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $324.68 | 42.5% | 19 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.36 | 4.1% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $20.71 | 2.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $15.70 | 2.0% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.67 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $764.34 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $357.22 | 25 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $324.68 | 19 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 225 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
225 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Risperidone | Risperidone | 1398 | 158 |
| Quetiapine Fumarate | Quetiapine Fumarate | 1172 | 117 |
| Clonazepam | Clonazepam | 1168 | 127 |
| Benztropine Mesylate | Benztropine Mesylate | 996 | 128 |
| Trazodone Hcl | Trazodone Hcl | 951 | 147 |
| Sertraline Hcl | Sertraline Hcl | 937 | 122 |
| Olanzapine | Olanzapine | 912 | 99 |
| Lorazepam | Lorazepam | 887 | 121 |
| Divalproex Sodium Er | Divalproex Sodium | 680 | 83 |
| Alprazolam | Alprazolam | 668 | 87 |
| Aripiprazole | Aripiprazole | 611 | 95 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 575 | 103 |
| Clozapine | Clozapine | 532 | 31 |
| Buspirone Hcl | Buspirone Hcl | 484 | 66 |
| Divalproex Sodium | Divalproex Sodium | 438 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 412 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 368 | 58 |
| Oxcarbazepine | Oxcarbazepine | 365 | 45 |
| Haloperidol | Haloperidol | 353 | 41 |
| Bupropion Xl | Bupropion Hcl | 344 | 55 |
| Paroxetine Hcl | Paroxetine Hcl | 341 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 318 | 42 |
| Mirtazapine | Mirtazapine | 317 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 297 | 47 |
| Gabapentin | Gabapentin | 265 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 252 | 32 |
| Topiramate | Topiramate | 240 | 27 |
| Lurasidone Hcl | Lurasidone Hcl | 229 | 32 |
| Invega Sustenna | Paliperidone Palmitate | 225 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 214 | 30 |
| Ziprasidone Hcl | Ziprasidone Hcl | 195 | 21 |
| Diazepam | Diazepam | 188 | 27 |
| Lamotrigine | Lamotrigine | 176 | 27 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 161 | 18 |
| Perphenazine | Perphenazine | 160 | 21 |
| Haloperidol Decanoate | Haloperidol Decanoate | 151 | 14 |
| Fluphenazine Hcl | Fluphenazine Hcl | 132 | 16 |
| Carbamazepine Er | Carbamazepine | 130 | suppressed |
| Temazepam | Temazepam | 114 | 13 |
| Propranolol Hcl | Propranolol Hcl | 113 | 17 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 110 | 17 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 109 | 11 |
| Olanzapine Odt | Olanzapine | 106 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 102 | 20 |
| Lithium Carbonate | Lithium Carbonate | 97 | 17 |
| Abilify Maintena | Aripiprazole | 94 | 13 |
| Lithium Carbonate Er | Lithium Carbonate | 77 | 11 |
| Carbamazepine | Carbamazepine | 70 | suppressed |
| Risperidone Er | Risperidone Microspheres | 70 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 60 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 59 | suppressed |
| Clozapine Odt | Clozapine | 56 | suppressed |
| Paliperidone Er | Paliperidone | 55 | suppressed |
| Risperidone Odt | Risperidone | 55 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 54 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 54 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | suppressed |
| Clozaril | Clozapine | 46 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 46 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 38 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 36 | suppressed |
| Aristada | Aripiprazole Lauroxil | 35 | suppressed |
| Thiothixene | Thiothixene | 34 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Saphris | Asenapine Maleate | 32 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Vraylar | Cariprazine Hcl | 29 | suppressed |
| Amantadine | Amantadine Hcl | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 27 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 27 | suppressed |
| Zyprexa Zydis | Olanzapine | 26 | suppressed |
| Caplyta | Lumateperone Tosylate | 25 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Austedo Xr | Deutetrabenazine | 21 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 20 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 20 | suppressed |
| Fanapt | Iloperidone | 19 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 19 | suppressed |
| Latuda | Lurasidone Hcl | 18 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 18 | suppressed |
| Ingrezza | Valbenazine Tosylate | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Metformin Hcl | Metformin Hcl | 17 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 16 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Geodon | Ziprasidone Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Xanax | Alprazolam | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 12 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Lexapro | Escitalopram Oxalate | 11 | suppressed |
| Lithobid | Lithium Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $764.34 · 49 records | ABBVIE INC. | ARISTADA, CAPLYTA, COBENFY, INVEGA SUSTENNA, INVEGA TRINZA, LYBALVI, Qelbree, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error